Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Calidi Biotherapeutics, Inc. (CLDI : AMEX)

• Company Description    Calidi Biotherapeutics Inc. is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer with a novel stem cell-based therapy. Calidi Biotherapeutics Inc., formerly known as First Light Acquisition Group, is based in SAN DIEGO. Number of Employees: 29

• Price / Volume Information    Yesterday's Closing Price: $0.18 Daily Weekly Monthly 20 Day Moving Average: 9,954,803 shares Shares Outstanding: 10.90 (millions) Market Capitalization: $1.92 (millions) Beta: 1.38 52 Week High: $13.20 52 Week Low: $0.16 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -20.09% -23.99% 12 Week -79.22% -80.79% Year To Date -84.97% -84.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4475 EXECUTIVE DRIVE SUITE 200 - SAN DIEGO,CA 92121 USA ph: 858-794-9600 fax: - ir@calidibio.com https://calidibio.com

• General Corporate Information    Officers Eric Poma - Chief Executive Officer and Director James A. Schoeneck - Chairman of the Board Andrew Jackson - Chief Financial Officer Allan J. Camaisa - Director Alan R. Stewart - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 320703408 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/14/26 Share - Related Items Shares Outstanding: 10.90 Most Recent Split Date: 8.00 (0.08:1) Beta: 1.38 Market Capitalization: $1.92 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.39 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 80.10% vs. Previous Quarter: 24.56% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -424.58 12/31/25 - -392.48 09/30/25 - -431.43 ROA 03/31/26 - -182.38 12/31/25 - -168.71 09/30/25 - -152.00 Current Ratio 03/31/26 - 1.92 12/31/25 - 1.59 09/30/25 - 2.12 Quick Ratio 03/31/26 - 1.92 12/31/25 - 1.59 09/30/25 - 2.12 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.45 12/31/25 - 0.52 09/30/25 - 1.04 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.15 12/31/25 - 0.21 09/30/25 - 0.11 Debt-to-Capital 03/31/26 - 13.15 12/31/25 - 17.02 09/30/25 - 9.97

Powered by Zacks Investment Research ©